Header Logo

Connection

Douglas Golenbock to Lymphocyte Antigen 96

This is a "connection" page, showing publications Douglas Golenbock has written about Lymphocyte Antigen 96.
Connection Strength

2.724
  1. Meng J, Gong M, Bj?rkbacka H, Golenbock DT. Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions. J Immunol. 2011 Oct 01; 187(7):3683-93.
    View in: PubMed
    Score: 0.378
  2. Meng J, Drolet JR, Monks BG, Golenbock DT. MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA. J Biol Chem. 2010 Sep 03; 285(36):27935-43.
    View in: PubMed
    Score: 0.349
  3. Meng J, Lien E, Golenbock DT. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J Biol Chem. 2010 Mar 19; 285(12):8695-702.
    View in: PubMed
    Score: 0.336
  4. Fitzgerald KA, Golenbock DT. Immunology. The shape of things to come. Science. 2007 Jun 15; 316(5831):1574-6.
    View in: PubMed
    Score: 0.283
  5. Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT. MD-2. Immunobiology. 2006; 211(6-8):437-47.
    View in: PubMed
    Score: 0.266
  6. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 2005 Nov 15; 175(10):6465-72.
    View in: PubMed
    Score: 0.254
  7. Yang H, Wang H, Ju Z, Ragab AA, Lundb?ck P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015 Jan 12; 212(1):5-14.
    View in: PubMed
    Score: 0.119
  8. Sandanger ?, Ryan L, Bohnhorst J, Iversen AC, Husebye H, Halaas ?, Landr? L, Aukrust P, Fr?land SS, Elson G, Visintin A, ?ktedalen O, Dam?s JK, Sundan A, Golenbock D, Espevik T. IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients. J Immunol. 2009 Jan 01; 182(1):588-95.
    View in: PubMed
    Score: 0.079
  9. Jain V, Halle A, Halmen KA, Lien E, Charrel-Dennis M, Ram S, Golenbock DT, Visintin A. Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling. Blood. 2008 May 01; 111(9):4637-45.
    View in: PubMed
    Score: 0.074
  10. Taylor KR, Yamasaki K, Radek KA, Nardo AD, Goodarzi H, Golenbock D, Beutler B, Gallo RL. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007 Jun 22; 282(25):18265-18275.
    View in: PubMed
    Score: 0.070
  11. Visintin A, Halmen KA, Khan N, Monks BG, Golenbock DT, Lien E. MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4). J Leukoc Biol. 2006 Dec; 80(6):1584-92.
    View in: PubMed
    Score: 0.067
  12. Cario E, Golenbock DT, Visintin A, R?nzi M, Gerken G, Podolsky DK. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J Immunol. 2006 Apr 01; 176(7):4258-66.
    View in: PubMed
    Score: 0.065
  13. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res. 2005; 11(6):363-8.
    View in: PubMed
    Score: 0.060
  14. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 2004 Dec; 6(15):1361-7.
    View in: PubMed
    Score: 0.059
  15. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003 Nov 28; 278(48):48313-20.
    View in: PubMed
    Score: 0.054
  16. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med. 2002 May; 30(5 Suppl):S207-13.
    View in: PubMed
    Score: 0.050
  17. Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, Golenbock DT. Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol. 2001 Dec 15; 167(12):7069-76.
    View in: PubMed
    Score: 0.048
  18. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med. 2001 Jul 02; 194(1):79-88.
    View in: PubMed
    Score: 0.047
  19. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol. 2005 Sep; 289(3):H1069-76.
    View in: PubMed
    Score: 0.015
  20. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun; 6(6):571-8.
    View in: PubMed
    Score: 0.015
  21. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002 Dec 06; 277(49):47834-43.
    View in: PubMed
    Score: 0.013
  22. Medvedev AE, Henneke P, Schromm A, Lien E, Ingalls R, Fenton MJ, Golenbock DT, Vogel SN. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol. 2001 Aug 15; 167(4):2257-67.
    View in: PubMed
    Score: 0.012
  23. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001 Mar 15; 166(6):4074-82.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.